Global Diabetes Drug Market Analysis

The global diabetes drug market is projected to reach USD 107.02 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.06% from 2024 to 2032. In 2023, the market size was valued at USD 63.02 billion, reflecting the rising demand for medications that manage both Type 1 and Type 2 diabetes. This surge is driven by a combination of increasing diabetes prevalence, advances in drug therapies, and a growing emphasis on public health awareness.

Request a free sample copy of the report: https://www.renub.com/diabetes-drug-market-p.php

What Is Diabetes and Why Is It Growing?

Diabetes is a chronic condition characterized by high blood sugar levels (hyperglycemia) due to the body's inability to properly produce or use insulin, a hormone essential for regulating blood glucose. There are two main types of diabetes:

• Type 1 Diabetes (T1D): An autoimmune disorder where the body's immune system attacks the insulin-producing cells in the pancreas. People with Type 1 diabetes require lifelong insulin therapy.
• Type 2 Diabetes (T2D): A condition where the body either becomes resistant to insulin or does not produce enough of it. This type is often linked to lifestyle factors like obesity, lack of exercise, and poor diet. T2D can often be managed with lifestyle changes and oral medications, but in some cases, injectable medications or insulin may be necessary.

The rising global prevalence of diabetes—both Type 1 and Type 2—has led to an increase in the demand for effective diabetic drugs. According to the World Health Organization (WHO), approximately 422 million people worldwide suffer from diabetes, and the disease is directly responsible for 1.5 million deaths annually.

Global Diabetes Drug Market Trends

1. Increase in the Prevalence of Diabetes

The escalating prevalence of diabetes is one of the primary drivers of the global diabetes drug market. As per The Lancet, the number of people living with diabetes is expected to exceed 1.31 billion by 2050. Currently, Type 2 diabetes accounts for approximately 90% of all diabetes cases globally. This rise is largely driven by increasing rates of obesity, poor dietary habits, and sedentary lifestyles, especially in developed countries, but also increasingly in developing regions.

The National Institutes of Health (NIH) reports that there were over 500,000 new cases of Type 1 diabetes in 2023, and the number of people living with Type 1 diabetes worldwide is expected to rise to between 13.5 million and 27.4 million by 2040.

2. Public Awareness Campaigns and Education

Public awareness campaigns have played a crucial role in educating the public about diabetes prevention, management, and treatment options. For example, the World Health Organization’s "Access to Diabetes Care" campaign—launched on World Diabetes Day in 2023—aims to increase access to essential diabetes care services, including medications, technology, and support. These initiatives have encouraged more people to seek medical advice and medications, driving the growth of the diabetes drug market.

In many regions, awareness of diabetes risk factors, symptoms, and treatment options is still limited, and significant efforts are needed to address this gap. Efforts to raise awareness about diabetes and its complications are directly contributing to the growth of the diabetes drug market.

3. Approval of New Drugs and Therapies

As the incidence of diabetes continues to rise, pharmaceutical companies are rapidly developing and receiving approvals for new drugs aimed at better managing the condition. One notable example is the approval of Bexagliflozin (Brenzavvy) by the U.S. Food and Drug Administration (FDA) in January 2023. This new drug has been authorized for the treatment of Type 2 diabetes and is expected to contribute significantly to the global diabetes drug market's growth.

Other advancements in diabetes drug therapies include the development of GLP-1 receptor agonists, SGLT2 inhibitors, and combination therapies that offer better efficacy and convenience for patients, especially those who require insulin.

4. Expanding Access to Medication and Lower Costs

In response to the rising global demand for diabetes drugs, companies and governments are increasingly focused on improving access to affordable medication. For example, Glenmark Pharmaceuticals Ltd. introduced a biosimilar version of the anti-diabetic drug Ligutide in India in January 2024. This version, sold under the brand name LirafitTM, is expected to reduce therapy costs by about 70%, making it more accessible to a broader population in developing regions.

In addition, the entry of generics and biosimilars into the market has helped bring down prices, improving access for underserved populations, especially in low- and middle-income countries.

Regional Market Insights

United States Diabetes Drug Market

The United States is the largest market for diabetes drugs, accounting for a significant share of the global diabetes drug market. As of recent estimates, about 37 million Americans—adults and children—are living with diabetes. The American Diabetes Association (ADA) reports that 352,000 children and teenagers under 20 have been diagnosed with diabetes, and Type 2 diabetes is increasingly being diagnosed in younger populations due to lifestyle changes.

The U.S. market continues to expand with new drug approvals, such as Eli Lilly's Mounjaro, which was approved as a weight-loss medication in November 2023. This dual-use drug, aimed at managing both diabetes and obesity, reflects the growing trend of combining diabetes management with weight-loss therapies.

Global Diabetes Drug Company News

Leading pharmaceutical companies are at the forefront of developing and distributing diabetes drugs globally. Some of the top players in the market include:

• Novo Nordisk
• AstraZeneca plc
• Biocon
• Sanofi
• Eli Lilly
• Johnson & Johnson
• Bristol Myers Squibb Co.
• Novartis AG

These companies are consistently innovating in the diabetes space, with several new drug launches and acquisitions making headlines in recent months.

• In January 2024, Glenmark Pharmaceuticals launched a biosimilar version of Ligutide in India, helping to reduce costs for diabetic patients in the region.
• In December 2023, Carmot Therapeutics, a U.S.-based weight-loss drug manufacturer, was acquired by Roche for $2.7 billion. Carmot’s portfolio includes drugs for both diabetes and obesity treatment, marking a significant development in the integration of diabetes and weight management therapies.
• In October 2023, Glenmark Pharmaceuticals introduced a triple-fixed-dose combination (FDC) drug for diabetes treatment, combining Teneligliptin, Dapagliflozin, and Metformin under the brand name Zita.

Related Report :

United States Diabetes Device Market

Germany Diabetes Device Market

United Kingdom Diabetes Device Market

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)

Email: mailto:rajat@renub.com